Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).

Abstract

BACKGROUND:

Radiotherapy (RT) following breast-conserving surgery (BCS) is mainly used to decrease the rate of ipsilateral breast tumor recurrence (IBTR) in women with breast ductal carcinoma in situ (DCIS). Recent studies have demonstrated that low-dose tamoxifen significantly reduces IBTR in breast DCIS. Here, we aim to determine whether the administration of low-dose tamoxifen is non-inferior to RT in preventing IBTR in patients with low-risk characteristics of breast DCIS.

METHODS/DESIGN:

This is a prospective, international, open-label, randomized, non-inferiority trial. Patients with low-risk clinicopathologic features (> 40 years old, low risk of breast cancer susceptibility gene (BRCA) 1 and BRCA2 mutations, mammographically detected unicentric and non-mass lesions, low- or intermediate-grade without comedo or necrosis, measuring < 2.5 cm with margins ≥ 3 mm, and estrogen receptor-positive status) of DCIS who underwent BCS will be randomized at a 1:1 ratio to either receive tamoxifen (5 mg/day) for 5 years or undergo RT with conventional fractions (50 Gy in 25 fractions) or hypofractionations (40.05 Gy in 15 fractions). Randomization will be stratified by the Taiwan Breast Cancer Consortium. As approximately 5% of patients cannot tolerate the side effects of low-dose tamoxifen and will receive RT, we estimate that 405 patients will be randomized to a low-dose tamoxifen arm and 405 patients to the RT arm, according to a non-inferiority margin within 5% of IBTR difference and 90% β-power noticing non-inferiority. The primary endpoints are breast tumor recurrence, including ipsilateral, regional, contralateral, and distant recurrence of breast DCIS or invasive cancer. The secondary endpoints are overall survival and adverse effects of RT and tamoxifen. Translational studies will also be conducted for this trial.

DISCUSSION:

This is the first non-inferiority trial on breast DCIS. This study will provide an important recommendation for clinical physicians on whether to use low-dose adjuvant tamoxifen for patients with low-risk breast DCIS who do not want to receive adjuvant RT.

TRIAL REGISTRATION:

ClinicalTrials.gov, ID: NCT04046159, Registered on April 30, 2019.

• Authors: Sung-Hsin Kuo, Ling-Ming Tseng, Shou-Tung Chen, Yasuaki Sagara, Yuan-Ching Chang, Hsien-Tang Yeh, Yao-Lung Kuo, Chih-Chiang Hung, Tzu-Pin Lu, Yi-Hsuan Lee, Masakazu Toi, Chiun-Sheng Huang
• Journal: BMC cancer (BMC Cancer) Vol. 23 Issue 1 Pg. 865 (Sep 14 2023) ISSN: 1471-2407 [Electronic] England
• PMID: 37710198 (Publication Type: Randomized Controlled Trial, Equivalence Trial, Journal Article)
• Copyright: © 2023. BioMed Central Ltd., part of Springer Nature.

Chemical References

• Receptors, Estrogen
• Tamoxifen

Topics

• Humans
• Female
• Adult
• Carcinoma, Intraductal, Noninfiltrating (drug therapy, surgery)
• Receptors, Estrogen
• Mastectomy, Segmental
• Tamoxifen (therapeutic use)
• Neoplasm Recurrence, Local (prevention & control)
• Prospective Studies
• Breast Neoplasms (drug therapy, genetics, surgery)
• Drug-Related Side Effects and Adverse Reactions